BOBULSKY SUSAN sold $31K of ADPT

BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 1,299 shares of Adaptive Biotechnologies Corp (ADPT) at $24.00 on 2026-07-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BOBULSKY SUSAN
Published Aug 3, 2026, 10:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may log the transaction for sentiment monitoring, but it is unlikely to drive a fresh repricing without additional company-specific catalysts.

03

What to watch

The sale size is small relative to typical institutional float, and the article provides no accompanying changes in guidance, trials, or financing that would make the transaction decision-relevant.

Relevance 2/10Novelty 3/10Timing: Filed 2026-08-03 after-hours; reflects sale executed 2026-07-30.

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Adaptive Biotechnologies disclosed a Chief Commercial Officer’s open-market sale of 1,299 shares at $24.00 on 2026-07-30 via Form 4.

Expected impact

Likely minimal impact on the stock price; any effect is typically short-lived and outweighed by broader company catalysts.

Evidence & confidence

The filing is an insider transaction (S code) explicitly tied to a pre-arranged Rule 10b5-1 plan, which generally reduces interpretive value versus discretionary selling.

Market effects

No sector-level read-through; this is company-specific insider liquidity activity.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of reduced confidence, so traders may still watch for follow-on selling or other negative disclosures.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider transaction disclosure.

  • BOBULSKY SUSAN

    Chief Commercial Officer, MRD, who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.